Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells
Author(s) -
Jing Wang,
Yuko Shirota,
Defne Bayık,
Hidekazu Shirota,
Debra Tross,
James L. Gulley,
Lauren V. Wood,
Jay A. Berzofsky,
Dennis M. Klinman
Publication year - 2015
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1402004
Subject(s) - tlr7 , myeloid derived suppressor cell , immune system , macrophage , suppressor , biology , function (biology) , immunotherapy , myeloid , cancer research , cancer immunotherapy , immunology , myeloid cells , immunosuppression , microbiology and biotechnology , gene , innate immune system , in vitro , toll like receptor , biochemistry
Tumors persist by occupying immunosuppressive microenvironments that inhibit the activity of tumoricidal T and NK cells. Monocytic myeloid-derived suppressor cells (mMDSC) are an important component of this immunosuppressive milieu. We find that the suppressive activity of mMDSC isolated from cancer patients can be reversed by treatment with TLR7/8 agonists, which induce human mMDSC to differentiate into tumoricidal M1-like macrophages. In contrast, agonists targeting TLR1/2 cause mMDSC to mature into immunosuppressive M2-like macrophages. These two populations of macrophage are phenotypically and functionally discrete and differ in gene expression profile. The ability of TLR7/8 agonists to reverse mMDSC-mediated immune suppression suggests that they might be useful adjuncts for tumor immunotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom